MONDAY, Nov. 22, 2021 (HealthDay News) — Physiotherapist David Putrino was working on a vibrating glove to help deaf people experience live music when a friend mentioned that the same technology might stop tremors in people with Parkinson’s disease. Putrino, director of rehabilitation innovation for Mount Sinai Health System inContinue Reading

MONDAY, Nov. 22, 2021 (HealthDay News) — Most prescriptions for the medication gabapentin are for unapproved uses — and many patients end up taking it along with drugs that create potentially dangerous interactions. That’s the conclusion of a new study that looked at “off-label” use of gabapentin. In the UnitedContinue Reading

MONDAY, Nov. 22, 2021 (HealthDay News) — Tight blood pressure control — not too high and not too low — during surgery for spinal cord injuries may improve patients’ outcomes, a new study suggests. “Damage to neurons in spinal cord injuries leads to dysregulation of blood pressure, which in turnContinue Reading

FRIDAY, Nov. 19, 2021 (HealthDay News) — Guidelines for treating movement problems in people in the early stages of Parkinson’s disease have been updated. The new treatment recommendations from the American Academy of Neurology (AAN) focus on dopaminergic medications, which increase dopamine levels or mimic dopamine effects. Parkinson’s is aContinue Reading

THURSDAY, Nov. 18, 2021 (HealthDay News) — Neurologists must make sure Alzheimer’s patients and their families understand that the controversial drug aducanumab does not restore mental function, the American Academy of Neurology (AAN) said in new position statement that includes ethical guidelines. “Aducanumab is not a cure for Alzheimer’s disease,Continue Reading

WEDNESDAY, Nov. 17, 2021 (HealthDay News) — The first human clinical trial of a nasal vaccine to slow the progression of Alzheimer’s disease is set to begin after nearly 20 years of research. This is a “remarkable milestone,” according to Dr. Howard Weiner, co-director of the Ann Romney Center forContinue Reading

MONDAY, Nov. 15, 2021 (HealthDay News) — A new and expensive Alzheimer’s drug called Aduhelm is responsible for about half of the $21.60 increase in monthly premiums for Medicare’s Part B outpatient program in 2022, Medicare officials report. The new premium will be $170.10 a month, and the $21.60 boostContinue Reading